Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 14/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7533440 | 1.00 | KDM4E (0.48) | KDM4EEPHX1ALDH1A1L3MBTL1EPHX2 | |
| SCHEMBL3071012 | 1.00 | KDM4E (0.48) | KDM4EEPHX1ALDH1A1L3MBTL1EPHX2 | |
| SCHEMBL7525000 | 0.99 | KDM4E (0.46) | KDM4EEPHX1ALDH1A1L3MBTL1EPHX2 | |
| SCHEMBL8608808 | 0.95 | KDM4E (0.45) | KDM4EEPHX1ALDH1A1L3MBTL1EPHX2 | |
| SCHEMBL3055428 | 0.90 | ABCB1 (0.45) | KDM4EALDH1A1L3MBTL1ABCB1 | |
| SCHEMBL27493475 | 0.84 | ALDH1A1 (0.51) | KDM4EALDH1A1L3MBTL1ABCB1USP2 | |
| Fumaric Acid SCHEMBL7526322 | 0.82 | EPHX2 (0.40) | KDM4EALDH1A1EPHX2ABCB1USP2 | |
| Maleic Acid SCHEMBL7526315 | 0.82 | EPHX2 (0.40) | KDM4EALDH1A1EPHX2ABCB1USP2 | |
| Hydrochloric Acid SCHEMBL3077107 | 0.82 | ALDH1A1 (0.53) | KDM4EALDH1A1L3MBTL1ABCB1USP2 | |
| SCHEMBL3064749 | 0.81 | KDM4E (0.54) | KDM4EEPHX1ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6143741-A | TREATING OR PREVENTING ILLNESSES RESULTING FROM DAMAGED ENDOTHELIAL CELLS SUCH AS ATHEROSCLEROSIS, THROMBOSIS, RESTENOSIS, VESSEL SPASM BY ADMINISTERING HYDROXYLAMINE DERIVATIVE | BIOREX Kutato es Fejleszo Rt. (HU) | 2000-11-07 | — | — | US | claimed |
| US-20100267711-A1 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF | CYTRX CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-7745465-B2 | Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof | CYTRX CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7148239-B2 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | CYTRX CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| US-20040067940-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | BIOREX RESEARCH & DEVELOPMENT CO. | 2004-04-08 | — | — | US | disclosed |
| US-20040019103-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | BIOREX RESEARCH & DEVELOPMENT CO. | 2004-01-29 | — | — | US | disclosed |
| US-6653326-B1 | For example, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-3-pyridinecarboximidoyl chloride maleate; inducing gene expression of an eukaryotic cell under physiological stress; antiallergens; autoimmune diseases; cardiovascular disorders | BIOREX RESEARCH & DEVELOPMENT CO. (HU) | 2003-11-25 | — | — | US | disclosed |
| EP-0801649-B1 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | BIOREX KUTATO FEJLESZTOE KFT (HU) | 2002-08-07 | — | — | EP | disclosed |
| EP-0832079-B1 | ANTI-ISCHAEMIC HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | BIOREX KUTATO FEJLESZTOE KFT (HU) | 2002-03-27 | — | — | EP | disclosed |
| US-6143741-A | TREATING OR PREVENTING ILLNESSES RESULTING FROM DAMAGED ENDOTHELIAL CELLS SUCH AS ATHEROSCLEROSIS, THROMBOSIS, RESTENOSIS, VESSEL SPASM BY ADMINISTERING HYDROXYLAMINE DERIVATIVE | BIOREX Kutato es Fejleszo Rt. (HU) | 2000-11-07 | — | — | US | disclosed |
| EP-1018876-A1 | USE OF HYDROXYLAMINE DERIVATIVES, AND METHOD AND PREPARATIONS FOR INCREASING THE TOLERANCE OF FIELD CROPS AGAINST WEATHER STRESSES | BIOREX KUTATO ES FEJLESZTÖ RT. (HU) | 2000-07-19 | — | — | EP | disclosed |
| US-6002002-A | Anti-ischaemic hydroxylamine derivatives and pharmaceutical compositions | BIOREX RESEARCH & DEVELOPMENT CO. (HU) | 1999-12-14 | — | — | US | disclosed |
| WO-1998047362-A1 | USE OF HYDROXYLAMINE DERIVATIVES, AND METHOD AND PREPARATIONS FOR INCREASING THE TOLERANCE OF FIELD CROPS AGAINST WEATHER STRESSES | Biorex Kutató és Fejlesztó Rt. (HU) | 1998-10-29 | — | — | WO | disclosed |
| EP-0832079-A1 | ANTI-ISCHAEMIC HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | BIOREX KUTATO ES FEJLESZTÖ RT. (HU) | 1998-04-01 | — | — | EP | disclosed |
| EP-0801649-A2 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | BIOREX KUTATO ES FEJLESZTÖ RT. (HU) | 1997-10-22 | — | — | EP | disclosed |
| WO-1997016439-A1 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | Biorex Kutató és Fejlesztó Rt. (HU) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997000251-A1 | ANTI-ISCHAEMIC HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | BIOREX KUTATO ES FEJLESZTO RT. (HU) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267711-A1 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF | HSPE1, HSF1, HSP90AB2P | KDM4E 3328/4885EPHX1 2282/4885ALDH1A1 533/4885 |
| US-20040019103-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | HSPE1, HSF1, HSPA1A | KDM4E 3243/4885EPHX1 2146/4885ALDH1A1 641/4885 |
| US-20040067940-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | HSPE1, HSF1, HSPA1A | KDM4E 3243/4885EPHX1 2146/4885ALDH1A1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.